Precision Engineering in Oncology: Advances and Applications of CRISPR Technology in Cancer Modeling Using Murine Models

Oojas Pardeshi [a,b*], Mohit Mahalle [a,b], Aditya Mahajan [a,b], Mayur Patil [a,b] and Yatharth Nandurkar [a,b]

[a] *Nagpur Veterinary College, Nagpur, India.*
[b] *Maharashtra Animal and Fishery Science University, Nagpur, India.*

Authors' contributions

This work was carried out in collaboration among all authors. Authors OP and MM outlined the headings and subheadings, and wrote the first draft of the manuscript. Authors AM, MP and YN managed the literature searches, designed the images using image software, created the tables, suggested changes to the first draft, and wrote the final draft. All authors read and approved the final manuscript.

Review Article

ABSTRACT

The innovative CRISPR-Cas9 system, which was awarded the Nobel Prize in Chemistry in 2020, has altered genetic manipulation, allowing researchers to better understand human illnesses. The CRISPR/Cas system, or "genetic scissors," developed by Nobel laureates Emmanuelle Charpentier and Jennifer Doudna, enables flexible and straightforward genome editing [1]. CRISPR/Cas9 has been widely used in cancer research, but it has now been extended to in vivo techniques, improving

human disease modelling [2]. Despite advances in cancer therapy, current medications have substantial toxicity and low success rates. Cancer researchers get insight into intricate tumor biology within dynamic physiological systems by using transgenic mice models [3]. Because of the complexities of the cancer genome, which includes multiple mutations, translocations, and chromosomal changes, exact models are required for thorough knowledge. CRISPR-Cas9 and its variations are RNA-guided nucleases that provide diverse and user-friendly platforms for site-specific genome editing, revolutionising gene editing by imitating genetic processes in human cancer cells [4]. CRISPR high throughput genetic screening and barcoding uncover genes associated with treatment resistance, metastasis, and carcinogenesis, allowing the monitoring and research of cancer cell adaptations [5]. This review focuses on how CRISPR-Cas9 has been used to create precise germline and somatic mice models, allowing researchers to better understand the evolution and course of individual tumours [6]. The successes and pitfalls of these techniques are discussed, emphasising their promise for improving functional cancer genomics and altering the landscape of precision cancer therapy. Future CRISPR breakthroughs promise more precise genome editing and complex cancer models, which will help understand tumor progression and design successful therapies.

Keywords: CRISPR-Cas9; In vivo modeling; transgenic mice models; precision cancer therapy; high throughput genetic screening; ethical considerations; tumor evolution; carcinogenesis Pathways; CRISPR barcoding; cancer research.

1. A DISCOVERY TIMELINE OF CRISPR CAS9 SYSTEM

CRISPR, an acronym for clustered regularly interspaced short palindromic repeats, was discovered in the DNA sequences of Escherichia coli bacterium in 1987 [7] at Osaka University in Japan. Despite the difficulty of sequencing these DNA snippets at the time, the origin and importance within the bacterial cell were not immediately appreciated by the researchers. Although the biological role of the CRISPR system was unknown in the early stages of study, scientists proposed using the information encoded in CRISPR loci to genotype various bacterial strains. This application was first investigated in Mycobacterium TB [8] and then in Streptococcus pyogenes [9]. In 1995, Francisco Mojica of the University of Alicante, Spain, identified comparable structures in the archaeal genome of Haloferax mediterranei, which was important in understanding the biological role of CRISPR loci [10]. The occurrence of these components across evolutionarily distant areas of life hinted to their significant functional significance, prompting additional investigation. Mojica noticed similarities between the new archaeal components and previously identified DNA repeats in bacterial genomes [11]. He was among the first to postulate that these unique loci are made up of foreign DNA pieces and are part of bacteria and archaea's immune systems [12]. In the same year, two additional independent laboratories found identical conclusions, kicking off active investigation into this extraordinary natural phenomenon [13,14]. In accordance with the notion of the prokaryotic immune system, clusters of viral DNA fragments known as "spacers," ranging from 17 to 84 bases in length and separated by short palindromic repeats (23-50 bases) [15], are located in intergenic areas. This arrangement creates a library of potentially dangerous genetic information, forming a microbial antiviral arsenl. Initially, it was assumed that the system worked by RNA interference. However, Marraffini and Sontheimer empirically established for the first time that the prokaryotic immune system's actual target is foreign DNA rather than mRNA. This finding showed that such a technology may be used in the laboratory for genome editing [16]. Subsequent research indicated that certain CRISPR systems do interact directly with RNA molecules [17,18], allowing selective deactivation of particular transcripts in cell [19,20]. The collaborative research of two French food scientists, Rodolphe Barrangou and Philippe Horvath, yielded the first insights into the operational mechanism of the CRISPR system in 2007. Their research using Streptococcus thermophilus bacteria in yoghurt for the Danish corporation Danisco was a watershed moment [21]. Using the company's enormous bacterial strain collection amassed since the 1980s, the researchers followed the historical history of bacterial spacer acquisition at the CRISPR locus in response to viral attacks by bacteriophages. The inclusion of new spacers during their research provided acquired immunity to novel types of bacteriophages in S. thermophilus. This observation resulted in the

authors obtaining one of the first CRISPR patents. Danisco began vaccination of bacterial strains in 2005 using CRISPR [1]. CRISPR repetitions are found in approximately half of the analysed bacterial genomes but not in eukaryotic or viral DNA sequences. The existence of CRISPR repeats in mitochondria was postulated in early studies that also introduced CRISPR in cyanobacteria [1]. This idea was based on the sequencing of mitochondrial plasmids from Vicia faba L. beans [22], with Mojica et al. citing these findings [11]. However, further research has failed to validate these findings [15].

During the original discoveries, different scientific groups used multiple acronyms for CRISPR, hindering the retrieval of early articles. Jansen officially coined the word "CRISPR" in 2002 [23], and Mojica recommended it in correspondence amongst the collaborating scientific groups [11]. The discovery of this distinctive adaptive immune defence system altered the modelling of many biological processes and earned the Nobel Prize in 2020.

2. NEED FOR PRECISION MOUSE CANCER MODELS

Cancer is the second leading cause of death worldwide behind cardiovascular disease [9]. Despite significant advances in cancer surgery, physical interventions have been demonstrated to enhance the likelihood of metastatic recurrences by encouraging cancer cell dissemination [24]. These therapies also increase pro-inflammatory mediators, angiogenic factors [25,26], and cancer-dependent adhesion molecules. As a result, while many treatments strive to improve tumour control specificity, genome editing technology has lately emerged as a feasible option to other, more invasive procedures such as surgeries, chemotherapies, and immunotherapies. Prior to genetic mouse models, cancer research depended on human tumour cell lines cultured in culture systems. Despite providing useful information, these systems limit the study of physiological tumour relationships. Many research use immunocompromised mice or subcutaneous implantation, which impedes immune responses and site-specific interactions. Ideal mice systems develop tumours that are genetically and morphologically similar to human equivalents. The use of mice models is critical for investigating tumour start, development, progression, and treatment response. Cancer biologists now have several genetic manipulation

strategies at their disposal. Choosing the proper technique for developing mouse cancer models is a critical first step, as is specifying the intended aims of individual models [23,27]. Cell and animal models are critical for improving our understanding of tumour biology [21] and serve as powerful preclinical platforms for evaluating novel drugs [2,28].

3. HISTORICAL DEVELOPMENT OF MOUSE CANCER MODELS

Cancer modelling has evolved through several stages, including the use of human tumour cell lines, xenografts, and genetically modified models [29]. Transgene expression or homologous recombination have historically been used in genetic manipulation techniques [30,31]. Over the last decade, programmable nucleases such as zinc-finger nucleases (ZFNs) and transcription-activator-like effector nucleases (TALENs) have improved precision [32]. By employing single-stranded guide RNA for specific genome targeting, the CRISPR-Cas9 system has exceeded ZFNs and TALENs. Cas9 reprogramming is made easier using RNA, allowing for specific genomic alterations. This ground-breaking approach has been used in a variety of experimental models, including human, mouse, rat, zebrafish, fruit fly, and rhesus monkey [33].

4. INTRODUCING CRISPR/CAS 9 SYSTEM

The CRISPR/Cas9 system consists of the Cas9 operon, which includes repetitions and spacers, and tracrRNA, a unique RNA that is situated close to the Cas9 operon and resembles several sequences in the system [34]. When a virus infects bacteria, a portion of the virus's genetic code known as the spacer sequence is introduced to the bacterial genome [35]. Following that, the Cas9 operon assists in the formation of a segment known as pre crRNA, which combines the newly inserted spacer with the host's DNA [36]. This pre-crRNA contains host and viral components [37]. Pre-crRNA converts into mature guide RNA (gRNA) by a series of steps involving tracrRNA, RNase III, Cas1, and Cas2 nucleases [38]. To make the CRISPR/Cas9 system work, the Cas9 endonuclease attaches to the gRNA, forming a Cas9/gRNA complex. This complex, led by the. gRNA, accurately cuts the target DNA at certain sites [39]. Cas9 proteins from different bacteria recognise diverse PAM sequences. Cas9 from Streptococcus pyogenes, for example,

recognises both the 'NGG' and the less robust 'NAG' PAM sequences [40]. The cut in the DNA occurs a few bases distant from the PAM sequence due to the action of two nuclease domains, the HNH domain and the RuvC-like nuclease [41]. Cas9 stays inactive unless guided by the gRNA, assuring precision [35]. After non-homologous end joining, the genomic sequence changes by adding or deleting base pairs, resulting in insertions or deletions (indels). This mechanism can cause changes in the genomic sequence, potentially resulting in loss of-function mutations in the targeted protein [42,43,40,44]. Alternatively, homologous end joining repair can be used in conjunction with a "repair template." This allows a desired genomic sequence to be added to the target of interest [45]. These are the basic principles behind CRISPR's genome editing.

5. VERSIONS OF CRISPR/CAS 9 SYSTEM

The wt-CRISPR-Cas9 (wild type) system is a microbial adaptive immune defence system product [45]. The Cas9 nuclease and a single guide RNA (sgRNA), a hybrid of trans-Nat [4,46,47]. The sgRNA connects with the target strand by base-pairing when the opposing DNA strand carries the protospacer-adjacent motif (PAM) sequence. This allows Cas9 to cut the DNA site-specifically, resulting in DNA double strand breaks (DSBs) [48]. The two catalytic domains of the wt-Cas9 nuclease, HNH and RuvC, cleave the target DNA strand while RuvC cleaves the opposing strand [4,49].

wt-Cas9 becomes dCas9 (dead) [50] due to inactive HNH and RuvC domains When combined with effectors such as fluorescent proteins or epigenetic modifiers [50,51,52,53], dCas9, as a DNA binding tool. Referred to as epigenome editing [54], this dCas9-effector system facilitates future therapeutic epigenetic modifications or the study of gene expressions linked to cancer. By combining dCas9 with different activator or repressor domains, this variation was created to be able to target any region of the genome without cleavage and to either up- or down-regulate the transcription of target genes. Chen and Huang identified an additional use for the dCas9 system [55]. There are drawbacks to the dCas9-effector approach. In the first place, all target loci are activated or suppressed by its one-directional control. Furthermore, there is a need to enhance its regulatory efficacy.


Fig. 1. CRISPR/Cas9 mechanism of action

Table 1. Versions of CRISPR

Version	Description	Application
wt-CRISPR-Cas9	The wild-type CRISPR-Cas9 system is a microbial adaptive immune defence mechanism. Cas9 nuclease and single guide RNA (sgRNA) are used to cause DNA double strand breaks (DSBs).	Site-specific DNA cleavage, genetic alterations, gene knockouts.
dCas9	Cas9 with deactivated HNH and RuvC domains. When coupled with effectors, it can be used to attach to DNA	Epigenome editing, gene expression research, and possible therapeutic epigenetic changes
Cas9D10A	Cas9D10A is a nickase variant of Cas9 that cleaves just one DNA strand, reducing NHEJ activation and increasing homologous directed repair effectiveness	High-fidelity HDR, precise gene modification and substitution in the mouse genome.
RCas9	RCas9 is a programmable single-strand RNA (ssRNA) cleavage tool generated by introducing an exogenous PAM-containing oligonucleotide (PAMmer) into CRISPR-Cas9	Targeting and cleaving small RNAs
dRCas9	When RCas9 is fused to effectors, its inactivated catalytic domains function as a site-specific ssRNA binding domain	Site-specific ssRNA binding and RNA studies

Cas9D10A (nickase) is a Cas9 variation intended for increased HDR efficiency [56]. The activation of NHEJ is reduced by this mutant because it cleaves only one DNA strand. Combining it with sgRNA and a homologous repair DNA template enables high-fidelity HDR, which makes it possible to precisely modify and replace genes in the mouse genome, something that was difficult to achieve with conventional transgenesis techniques.

Type II CRISPR, which is the source of CRISPR-Cas9, mainly targets DNA, although type III-B CRISPR can also cut RNA. The PAM sequence on the opposing DNA strand is necessary for sgRNA recognition, making targeting RNA seem implausible. The programmable single-strand RNA (ssRNA) cleavage tool RCas9 [57] can be created from CRISPR-Cas9 by inserting an exogenous PAM-containing oligonucleotide (PAMmer) as an artificial "opposite DNA strand". By inactivating its catalytic domains, RCas9 may be further reprogrammed into dRCas9, which functions as a site-specific ssRNA binding domain when fused to effectors.

6. TECHNIQUES OF CRISPR/CAS 9 DELIVERY

The liver was the focus of a pioneering CRISPR/Cas9 in vivo investigation. Hepatocytes were able to express Cas9 protein and sgRNA through intravenous injection of plasmids [58,46].

CRISPR caused PTEN and Trp53 mutations, which led to liver cancer.Plasmid delivery has the benefit of carrying a substantial payload because the coding sequence of the Cas9 protein is just 4.1 kbp long.Intravenous infusion of Cas9-edited hematopoietic stem progenitor cells has been used successfully to mimic myeloid malignancies in mice (59) and a Burkitt lymphoma model (60).

Several viruses are used, lentivirus being the first, because of their capacity to transport heavy loads [58]. The target cell can get sgRNA and the Cas9 genomic code thanks to lentivirus, which then integrates into the host genome to allow for ongoing expression. This guarantees high CRISPR effectiveness, but because guides are persistently expressed alongside Cas9, there are worries about off-target alterations [59]. Brain, pancreatic, lung, and breast malignancies have all been induced by lentivirus [60,61,62,6]. Although viral integration functions as a "fingerprint" and verifies sgRNA sequences, it may also encourage the onset of cancer, which presents a problem for the distribution of lentiviruses [63].

To prevent viral genome integration into target cells, adenoviruses and adeno-associated viruses deliver CRISPR/Cas9. Their ability to multiply during cell division, combined with their temporary presence and cell tropism, makes them advantageous for targeting many organ [64]. s. Adenoviruses are extremely harmful and

can cause tissue damage and cell death [64]. They are appropriate for the delivery of sgRNA and Cas9 because they have a broad tropism and can transport substantial payload.Adenoviruses are frequently used to transmit sgRNA and Cas9, causing in vivo cell transformation, especially in mice for brain and lung cancer [65].

Adeno-associated virus (AAV) differs from AV in that it is only capable of reproducing in cells that are also infected with AV [66]. AAV is not harmful, seldom integrates into the host genome, and can live in infected cells for more than a year. Integration normally happens at a specific place without interfering with gene expression [66]. Different AAV serotypes show great tropism for particular cell types, which enhances transduction and induces cancer at specific places [67]. AAV's cargo size limitation is that each virus particle may only contain about 5 kilobases. Because the Cas9 coding sequence is 4.1 kilobases long, the possibilities for delivering numerous sgRNAs with Cas9 are limited.

Fertilised eggs or blastocysts (for transformed ES cells) are classically microinjected to create transgenic mouse models harbouring CRISPR/Cas9-induced alterations in every cell in the body [3]. For NSCLC, basic epithelial cell transfection has also been employed to target genomic rearrangements (76).

Electroporation is an effective method of delivering modified sgRNAs in contact with the Cas9 protein (Cas9/sgRNA ribonucleoprotein complexes, or RNPs) in vitro [68]. RNPs, however, are ineffective for in vivo applications because their fast degradation and negative charge impair uptake [69]. Consequently, RNPs are packed into lipid nanoparticles for distribution to various organs. It has been possible to successfully modify genes to cause cancer in a variety of organs, Including the brain, liver, and lung. There have also been some reported successful attempts recently to electroporate pronuclear zygotes (74,75).

The hepatic delivery of CRISPR components targeting Pten and Trp53 was achieved in wild type mice treated with carbon tetrachloride as an accelerator of cancer using hydrodynamic tail vein injection. The animals developed cholangiocarcinomas that had histopathological characteristics that were very similar to those seen in conventional GEMM [62].

Cell-Penetrating Peptides (CPP), in conjunction with other transfection agents, were used in a recent study [70] to successfully transport sgRNA and recombinant Cas9 protein into human cells. Previous studies have demonstrated that CPPs are efficient mediators for in vivo transport of RNA [71] and protein [72], indicating a possible novel pathway for the administration of CRISPR-Cas9 components *In vivo.*

The development of a Cre-dependent Cas9 mouse by Platt et al. [73] provided a method for multigene pairings. The Rosa26 locus was altered to accept a floxed-stopped Cas9 expression cassette. They created successive genetic lesions in this animal by expressing three sgRNAs using a single AAV serotype9, an HDR donor template with the KrasG12D mutation, and Cre recombinase, proving that constitutive or tissue-specific Cas9 expression had no negative effects. Two months after infection, lung tumours developed in 100% of treated rats due to multiplex sgRNA delivery, which specifically targeted Kras, p53, and Lkb1.The avoidance of immunological reactions against somatic Cas9 expression, which may result in inflammation and the elimination of Cas9-expressing cells, is an advantage of Cas9 knockin mice [61,74].Analogously, reported on the application of Cas9 and Cas9D10A animal models that are doxycycline-inducible for inducible genome editing in mice [3].

7. CRISPR CANCER MODELS

Hepatocellular carcinomas that resembled those seen in conventionally generated mice with liver specific Pten and Trp53 loss were formed as a result of the hydrodynamic tail vein injection method of administering CRISPR/Cas9 components targeting Pten and Trp53 to the liver via a plasmid expressing Cas9 and sgRNAs [62]. The animals developed cholangiocarcinoma that exhibited histopathological characteristics that were similar to those seen in conventional GEMM [62].

Alb-Cre; KrasLSL-G12D/+ mice were multiplexed and hydrodynamic tail vein injection was performed using ten different CRISPR-SB vectors. Each vector, including Cas9 and one of 10 distinct sgRNAs flanked by Sleeping Beauty (SB) transposon repeats, was accompanied by an SB transposase vector to facilitate genomic integration. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma were the results of this strategy [5].

Fig. 2. Creating murine tumour models using various CRISPR/Cas delivery techniques

Using PEI-mediated transfection of the neonatal cerebellum or in utero electroporation of the developing prosencephalon, CRISPR cancer modelling in the brain was first accomplished [75]. While glioblastoma was produced by targeting Nf1, Pten, and Trp53, medulloblastoma was formed when the sonic hedgehog receptor Ptch1 was inactivated [75]. Subsequent research used cerebral injection of viral vectors containing CRISPR to imitate high-grade glioma [76,77]

Pancreatic cancer modelling strategies included retrograde pancreatic ductal [62], direct injection of CRISPR-carrying viruses into the pancreas [78,79], and CRISPR plasmid injection followed by in vivo electroporation [80,81]. Even if it is ineffective, in vivo electroporation allows transfected cells to absorb several plasmids, which facilitates in vivo multiplex mutagenesis. This method confirmed negative selection for Brca2 inactivation in KrasG12D-driven pancreatic cancer, enabling the first direct in vivo synthetic lethality screening [80].

Yang et al. showed that CRISPR-Cas9 is a viable tool for producing gene mutations as well as for designing malignant chromosomal rearrangements in mice and maybe other species in vivo [48]. The Eml4-Alk gene rearrangement recurrent in non-small-cell lung tumours was successfully produced. In order to introduce CRISPR components into adult mouse lung tissue, lentiviral particles were used either intrapulmonaryly or intratracheally. Two single-strand breaks (DSBs) caused by targeting the Eml4 and Alk genes on mouse chromosome 17 can occasionally result in 10-Mb inversions (1.5 rearrangements/106 cells).Maddalo et al. reported producing the Eml4-Alk inversion in adult mouse lung somatic cells in a different work [82].In order to produce loss-of-function mutations in p53, Lkb1, and HDR-mediated KrasG12D alterations, which mimicked the pathophysiology of lung adenocarcinoma, a single AAV vector was delivered into the lung [83].

Hematopoietic stem cells are used in ex vivo engineering, wherein they are transduced in vitro using CRISPR-Cas9 viral vectors and then transplanted into recipient mice. This permits the quick generation of novel mice models for haematological malignancies [84,85,86,87]. In a recent work, delivering combinations of sgRNAs and Cas9 via a lentiviral vector resulted in effective alteration of up to five genes in HSCs [84]. Utilising this method produced models of acute myeloid leukaemia through clonal expansion and the emergence of myeloid malignancy.

Using the CRISPR-Cas9 method [88] recently rearranged selected genomic intervals at six loci (H2afy, Bmp2, Ihh, Pitx1, Laf4, and Epha4) that

are associated to human illnesses. The genomic intervals ranged from 1 kb to 1.6 Mb. Deletions and inversions were identified at all sites, with duplications occurring in Pitx1 (0.7%) and Laf4 (28.1%). Notably, human malformation syndromes and neurological abnormalities were replicated by the deletion of 353 kb and 1.6 Mb genomic regions at the Laf4 and Epha4 loci, respectively [88].

Annunziato et al. utilised a mouse model with Wap promoter-driven Cre recombinase to achieve targeted Cas9 expression in the mammary epithelium. Four months after these mice received a mammary duct injection of a lentivirus expressing a sgRNA targeting Pten along with conditional Cdh1 gene deletion (E-cadherin), these mice developed tumours that resembled human lobular breast carcinomas [61].

8. CRISPR-CAS9 HIGH-THROUGHPUT GENETIC SCREENING

When screening a large number of genes, CRISPR/Cas9 gives a special advantage.In 2014, Zhang et al. carried out two important in vitro investigations [52,89]. First, genes linked to vemurafenib resistance in melanoma were identified by using the CRISPR-Cas9 knockout (GeCKO) library, which targets approximately 18,000 human genes for targeting. Both proven and fresh candidates were identified by this investigation. The second study used a sgRNA library to screen for genes that activate vemurafenib resistance. Using a genome wide loss-of-function sgRNA library, Zhang and Sharp [90] expanded on this strategy by methodically screening genes linked to metastasis. They mutated a non-metastatic lung cancer cell line, transplanted the mutant cells into mice, and used deep sequencing to identify a collection of genes consistently related with tumour growth and metastasis. In vitro screens have proved effective in laboratories due to the capacity to use a large number of cells, ensuring complete coverage of gene libraries holding 50,000 to 100,000 distinct sgRNAs. Applying these libraries to *In vivo* research is difficult, though. In response, particular gene groupings are the focus of in vivo screening. In an AAV vector, for example, Chow and Wang (2017 & 2018) generated a library including over 250 tumour suppressor genes, each represented by 5 distinct sgRNAs. Through the use of Tpr53-deficient mice and targeted genes such as Pen, they were able to effectively explore the formation of gliomas and HCCs [77,91].


Fig. 3. Various ways for making transgenic mice: (A) retroviral method, hardly used; (B) typical transgene strategy, introducing DNA into the genome non-specifically; and (C) gene-targeted

Fig. 4. CRISPR barcoding for genetic tracking

9. CRISPR BARCODING

The limited efficiency of HDR genome editing is exploited by CRISPR/Cas9 [92] to introduce oncogenic mutations selectively, monitoring modified cells through the use of a genetic barcode. We inserted a unique code, readable by sophisticated instruments, to track these transformed cells. This gave us the opportunity to investigate how cancer cells adapt and test various cancer treatments. This method uses a certain subgroup as an internal control. Since both control and mutant cells express the same sgRNA, off-target effects are prevented and specificity is increased. Different barcodes in the same cell's alleles are avoided by transfecting ssODN's (single stranded deoxyribonucleotides) separately with plasmids containing Cas9 and sgRNA. We demonstrated the usefulness of the approach in evaluating cancer medication combinations by applying it to tumour cell lines, where we generated TP53 mutations and amplified cells by Nutlin 3 treatment.The approach also studies effects on proliferation, invasion, and tumorigenicity in immunodeficient mice, modelling resistance mechanisms to EGF receptor inhibitors in non-small cell lung cancer [93].

10. CRISPR CHALLENGES IN GENOME EDITING

Non-Homologous End Joining (NHEJ) methods produce different indels in current CRISPR/Cas9-based gene editing for minor deletions and insertions, resulting in significant sequence changes in the resulting allelic series. Although indels usually result in loss-of-function alleles, they can also cause in-frame or out-of-frame indels due to their unpredictability and lack of control during base editing via NHEJ. This unpredictability poses complications, as most indels cause frame-shift mutations, but 3-base indels selectively modify amino acids without disturbing the reading frame. The CRISPR/Cas9 system's off-target editing activity, which has the potential to change the genome in unexpected ways, is a major cause for concern. Although research on human cells [94,95] has shown that off-target events occur somewhat often, preliminary findings in mouse embryos suggest that CRISPR/Cas9 off-target events are uncommon. Reduce and carefully monitor these off-target effects, especially in therapeutic applications, since they can cause epigenetic modifications, disturbances in gene activity, and instability of the genome. The transcription of the targeted gene may be inhibited by off-target effects, which might appear as binding to partly complementary target sequences but not cleaving them [92].

One issue in utilising CRISPR/Cas9 to simulate cancer in living creatures is successfully distributing the sgRNA and Cas9 protein. The organs that may be targeted are limited by this restriction, with the colon's crypt structure providing unique challenges. Current approaches

entail sophisticated procedures such as introducing Adeno-Associated Virus (AAV) to the mouse's prostatic lobes via surgery and complex injections. It is possible for this process to fail and for unwanted tumours to grow in other organs or to fail entirely, leaving the targeted organ without tumour start. Enhancing the efficiency of in vivo genome editing can be achieved by using split Cas9 [95,96] and better CRISPR delivery strategies, such as CRISPR proteins or mRNA. Furthermore, investigating smaller-sized Cas9 proteins may simplify the packaging of CRISPR viral vectors [97,98,99].

Furthermore, despite the fact that CRISPR-Cas9 has shown to be an adaptable research tool, the scientific community is still concerned about Cas9's safety [100]. More research is needed to thoroughly assess CRISPR-Cas9 safety. Furthermore, ethical concerns about manipulating the human germline will undoubtedly come up in the future [101].

10.1 Potential Solutions

The use of CRISPR/Cas9 raises the possibility of unforeseen consequences, or "off-target effects." Advanced techniques like ChIP-seq, GUIDE-seq [101], and Digenome-seq [102] are needed to identify these problems because the conventional methods may overlook some of them. Wang and colleagues [103] presented a lentiviral vector-based approach to identify Cas9's off-target effects.Researchers are attempting several strategies to reduce these unintentional consequences. Purified Cas9 proteins can be used to mitigate difficulties instead of introducing Cas9 genes into cells. This is because the proteins degrade rapidly, leading to fewer long-lasting issues with the instructions inside the cell. Utilising a "inducible" Cas9 is a further option; it reduces the possibility of unforeseen consequences by functioning momentarily. Reducing these effects has also been demonstrated to be possible with a modified version of Cas9. The guide RNA (sgRNA) may be made more responsive to alterations by trimming a tiny portion of it, which will lessen any unwanted consequences.To avoid tumour growth in secondary tissues, Cas9 expression might be tissue specific. Tissue-specific Cre expression can be implemented through the use of transgenic mice under Cre induction for Cas9. Conditional Cas9-expressing mice can be intercrossed with strains of tissue-specific animals for Cre expression. An approach is to clone a tissue-specific promoter, transport it within a viral particle, and use it to express Cre.

For in vivo CRISPR-Cas9 delivery, methods such as nanoparticles [104], cell penetrating peptides [70], and ultrasound-mediated gene transfer [105,106] which increases cell membrane permeability by using ultrasound—show promise. Without the need for additional transfection agents, a recent work effectively delivered sgRNA and recombinant Cas9 protein into human cells via CPP [70].

10.2 Future Horizons in Crispr Technology

Epigenetic enzymes that regulate epigenetic alterations such as methylation are being combined with dCas9 by researchers. For instance, dCas9 combined with the demethylase enzyme TET1 was utilised to induce the activation of a reporter gene by removing methylation from certain DNA locations in mice. A different research methylated a particular section of the mice's genome by fusing dCas9 with the DNA methyltransferase MQ1. These dCas9-enzyme fusions are anticipated to be important in the future for cancer modelling, as aberrant DNA methylation has been connected to cance rthus conducting "epi-modelling" of cancer or exerting therapeutic functions [107,108]. Through a technique called CRISPRa, dCas9 fusions may be used to increase gene expression. In order to do this, dCas9 is attached to activators such as VP64 and p65. These activators, when directed by sgRNAs, target certain DNA areas and enhance gene activity. In a CRISPRa study, for example, resistance mechanisms in a melanoma cell line with the BRAFV600E mutation were examined. Novel and well-known resistance mechanisms were detected by the screen. It is anticipated that CRISPRi/a systems will soon be used in vivo with mice models of cancer because reversible regulation of gene expression offers a closer match to human tumour genetics [53]. CRISPR interference, or CRISPRi, is an additional technique for studying loss of function. It functions by preventing the production of the targeted genes and directing repressors (such as the Kruppel associated box, or KRAB) to the transcriptional start site. Key regulators of early mesoderm development, such as the transcription factor FOXA2, were identified, for example, in a CRISPRi research conducted in human ES cells [109]. sgrnas that target 5,689 lncRNA loci's beginnings were employed in a human GBM cell line that expressed dCas9-KRAB in a recent in vitro CRISPRi investigation. As a result, several lncRNAs that increase glioma cells' sensitivity to radiation were discovered [110].

Advances in the CRISPR-Cas9 system will eventually allow for more accurate genome editing, which will increase our capacity to develop sophisticated cancer models. There may be other advantages to creating novel Cas9 fusion proteins, such as light-inducible dCas9[111,112]. Like with RNA-interference techniques [113], in vivo CRISPR screens [114] could reveal novel cancer driver genes.Furthermore, the development of accurate cancer mouse models using genome editing techniques is something we anticipate will help us better understand how individual tumours advance and devise efficient treatment plans.Precision cancer mouse models will play a crucial role in advancing precision cancer medicine [115-121].

11. CONCLUSION

To sum up, the revolutionary CRISPR-Cas9 system has evolved to be an adaptable and strong instrument in cancer modelling, providing hitherto unseen potential for genome editing and investigating many uses.It has greatly increased our understanding of oncogenic pathways, from inducing germline editing and somatic editing for modelling gene knockouts, knock-ins, and chromosomal rearrangements to systematic genome-wide study. Despite the immense promise of constructing sophisticated cancer models, obstacles like as off-target effects, delivery modalities, and the requirement for precise control continue. CRISPR high-throughput genetic screening and CRISPR Barcoding are effective methods for identifying genes related with drug resistance, metastasis, and carcinogenesis, allowing for the monitoring and research of cancer cell adaptations, as well as the testing of therapies. In any case, the dynamics of the CRISPR/Cas field, which was sparked by pioneering, groundbreaking work that transformed a bacterial immune system into a game-changing bio- technological tool, indicate that it is likely to undergo further unanticipated developments that will add new milestones to the tumour modelling toolbox.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Isaacson W. The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race, Simon and Schuster (New York, USA); 2021.
2. Tuveson DA, Jacks T. Technologically advanced cancer modeling in mice. Curr. Opin. Genet. Dev. 2002;12:105–110.
3. Dow LE, Fisher J, O'Rourke KP, Muley A, Kastenhuber ER, Livshits G, et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol. 2015;33: 390–4.
    DOI:10.1038/nbt.3155
4. Sanchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014;516:428–31.
5. Weber J, Öllinger R, Friedrich M, Ehmer U, Barenboim M, Steiger K, Heid I, Mueller S, Maresch R, Engleitner T, et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc. Natl. Acad. Sci. USA. 2015;112:13982–13987.
6. Sánchez-Rivera FJ, Papa Giannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, Joshi N Subbaraj L, Bronson RT, Xue W, et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014;516:428–431.
7. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakatura A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isoenzyme conversion in Escherichia coli, and identification of the gene product, J. Bacteriol. 1987;169:5429-5433.
    DOI: 10.1128/ jb.169.12.5429-5433.1987
8. Groenen PM, Bunschoten AE, Van Soolingen D, Van Embden JD. Nature of DNA polymor- phism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method, Mol. Microbiol. 1993;10:1057-1065.
    DOI:10.1111/ j.1365-2958.1993.tb00976.x.

9. Hoe N, Nakashima K, Grigsby D, Pan X, Dou SJ, Naidich S, et al. Rapid molecular genetic subtyping of serotype M1 group A Streptococcus strains, Emerg Infect. Diseases. 1999;5:254-263.
DOI: 10.3201/eid0502.990210.

10. Mojica FJM, Juez G, Rodriguez-Valera F. Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites, Mol. Microbiol. 1993;9:613-621.
DOI: 10.1111/j.1365-2958.1993.tb01721.x

11. Mojica FJM, Díez-Villaseñor C, Soria E, Juez G. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria, Mol. Microbiol. 2000;36:244-246.
DOI: 10.1046/j.1365-2958.2000.01838.x

12. Mojica FJM, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements, J. Mol. Evol. 2005;60:174-182.
DOI: 10.1007/ s00239-00 4-00 46-3.

13. Bolotin A, Quinquis B, Sorokin A, Dusko Eh- rlich S. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin, Microbiology. 2005;151:2551-2561,
DOI: 10.1099/ mic.0.280 48-0.

14. Pourcel C, Salvignol G, Vergnaud G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies, Microbiology. 2005;151:653-663.
DOI: 10.1099/mic.0.27437-0.

15. Popkov VA, Zorova LD, Korvigo IO, Silachev DN, Jankauskas SS, et al. Do mitochondria have an immune system? Biochemistry (Moscow). 2016;1:1229-1236.
DOI: 10.1134/ S0006297916100217.

16. Marraffini LA, Sontheimer EJ. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA, Science. 2008;322:1843-1845.
DOI: 10.1126/ science.1165771.

17. Shmakov S, Abudayyeh OO, Makarova KS, Wolf YI, Gootenberg JS, et al. Discovery and functional characterization of diverse class 2 CRISPR–Cas systems, Mol. Cell. 2015;60:385-397,
DOI: 10.1016/j.molcel.2015.10.008.

18. Shmakov S, Smargon A, Scott D, Cox D, Pyzocha NV, et al. Diversity and evolution of class 2 CRISPR–Cas systems, Nat. Rev. Microbiol. 2017;169-182.
DOI: 10.1038 nrmicro.2016.184.

19. Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector, Science. 2016;353: aaf5573.
DOI: 10.1126/ science.aaf5573.

20. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, et al. RNA targeting with CRIS- PR–Cas13, Nature. 2017;550:280-284.
DOI: 10.1038/nature24049.

21. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, et al. CRISPR provides acquired resistance against viruses in prokaryotes, Science. 2007; 315:1709-1712.

22. Flamand MC, Goblet JP, Duc GR, Briquet M, Zoutry M. Sequence and transcription analysis of mitochondrial plasmids isolated from cytoplasmic male-sterile lines of Vicia faba, Plant Mol. Biol. 1992;19:913-923.

23. Jansen R, Embden JDAV, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes, Mol. Microbiol. 2002;43:1565-1575.
DOI: 10.1046/j.1365-2958.2002.02839.x

24. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of 14. death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388:1459-544.

25. Van Der Bij GJ, Oosterling SJ, Beelen RHJ, Meijer S, Coffey JC, Van Egmond M. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann. Surg. 2009;249:727–734.

26. Oh BY, Kim KH, Chung SS, Hong KS, Lee RA. Role of β1-integrin in colorectal cancer: Case-control study. Ann. Coloproctol. 2014;30:61–70.

27. Knudson AG. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer. 2001;2:157–162.

28. Sharpless KB, Manetsch R. In situ click chemistry: A powerful means for lead discovery. Expert Opin. Drug Discov. 2006; 1:525–538.

29. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer. 2008;8:592–603.

30. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat. Rev. Cancer. 2007;7: 645– 658.

31. Capecchi MR. Altering the genome by homologous recombination. Science. 1989;244:1288– 1292.

32. Gaj T, Gersbach CA, Barbas CF, Talen ZFN, CRISPR/Cas-based methods for genome engineering.Trends Biotechnol. 2013;7:397–405.

33. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014; 157:1262–1278.

34. Chylinski K, Le Rhun A, Charpentier E. The tracrRNA and Cas9 families of type II CRISPR Cas immunity systems. RNA Biol. 2013;10:726–737.

35. Modell JW, Jiang W, Marraffini LA. CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity. Nature. 2017;544:101– 104.

36. Burmistrz M, Krakowski K, Krawczyk-Balska A. RNA-targeting CRISPR–cas systems and their applications. Int. J. Mol. Sci. 2020;21:1122.

37. Dyda F, Hickman AB. Mechanism of spacer integration links the CRISPR/Cas system to transposition as a form of mobile DNA. Mob. DNA. 2015;6.

38. Lone BA, Karna SKL, Ahmad F, Shahi N, Pokharel YR. CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering. Genet. Res. Int. 2018; 2018.

39. Vakulskas CA, Behlke MA. Evaluation and reduction of Crispr off-target cleavage events. Nucleic Acid Ther. 2019;29:167– 174.

40. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 2013;31:827–832.

41. Murovec J, Pirc Ž, Yang B. New variants of CRISPR RNA-guided genome editing enzymes. Plant Biotechnol. J. 2017;15: 917–926.

42. Jinek M, East A, Cheng A., Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. ELife. 2013;2: e00471.

43. Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013;31:230–232.

44. Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, et al. CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling. Cell. 2014; 159:440–455.

45. Kim H, Kim J-S. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014;15:321–34.

46. Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, et al. CRISPR mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514:380–5.

47. Choi PS, Meyerson M. Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun. 2014;5:3728. DOI:10.1038/ncomms4728

48. Yang H, Wang H, Jaenisch R. Generating genetically modified mice using CRISPR/Cas mediated genome engineering. Nat Protoc.2014;9: 1956–68.

49. Shao Y, Guan Y, Wang L, Qiu Z, Liu M, Chen Y, et al. CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. Nat Protoc. 2014;9:2493–512.

50. Gilbert LA, Larson MH, Morsut L, et al. CRISPR- mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013;154:442–51

51. Maeder ML, Linder SJ, Cascio VM, et al. CRISPR RNA-guided activation of endogenous human genes. Nat Methods 2013;10:977–9.

52. Konermann S, Brigham MD, Trevino AE, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 2015; 517:5838.

53. Gilbert LA, Horlbeck MA, Adamson B, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 2014;159:647–61

54. Rusk N. CRISPRs and epigenome editing. Nat Methods 2014;11:28.

55. Chen B, Huang B. Imaging genomic elements in living cells using CRISPR/Cas9. Methods Enzymol. 2014; 546:337–54.
DOI:10.1016/B978-0- 12-801185-0.00016-7

56. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819–23.

DOI:10.1126/ science.1231143

57. O'Connell MR, Oakes BL, Sternberg SH, et al. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature 2014;516:263–6.

58. Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, Waddington SN, Thrasher AJ, Muntoni F, Morgan JE.;et al. Lentiviral vectors can be used for full-length dystrophin gene therapy. Sci. Rep. 2017;7:44775.

59. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 2013;31:839–843.

60. Roper J, Tammela T, Cetinbas NM, Akkad A, Roghanian A, Rickelt S, Almeqdadi M, Wu K, Oberli MA, Sánchez-Rivera FJ, et al. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat. Biotechnol. 2017, 35, 569–576.

61. Annunziato S, Kas SM, Nethe M, Yücel H, Del Bravo, J.; Pritchard C, Bin Ali R, van Gerwen B, Siteur B, Drenth AP, et al. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev. 2016;30:1470–1480.

62. Chiou S-H, Winters IP, Wang J, Naranjo S, Dudgeon C, Tamburini FB, Brady JJ, Yang D, Grüner BM, Chuang C-H, et al. Pancreatic cancer modeling using retrograde viral vector delivery and In vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev. 2015;29:1576–1585.

63. Dong W, Kantor, B. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives. Viruses 2021, 13, 1288.

64. Crystal, R.G. Adenovirus: The First Effective In Vivo Gene Delivery Vector. Hum.Gene Ther. 2014, 25, 3–11.

65. Cheng, R.; Peng J, Yan Y, Cao P, Wang J, Qiu C, Tang L, Liu D, Tang L, Jin J, et al. Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9. FEBS Lett. 2014;588:3954–3958.

66. Daya S, Berns KI. Gene Therapy Using Adeno-Associated Virus Vectors. Clin. Microbiol. Rev. 2008;21:583–593.

67. Wu Z, Asokan A, Samulski RJ. Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy. Mol. Ther. 2006;14:316–327.

68. Hendel A, Bak R, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 2015;33:985–989.

69. Wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 2020;11:3232.

70. Ramakrishna S, Kwaku Dad AB, Beloor J, et al. Gene disruption by cell-penetrating peptide medi- ated delivery of Cas9 protein and guide RNA. Genome Res 2014;24:1020–7.

71. Li H, Zheng X, Koren V, et al. Highly efficient delivery of siRNA to a heart transplant model by a novel cell penetrating peptide-dsRNA binding domain. Int J Pharm 2014;469:206–13.

72. Boisguerin P, Redt-Clouet C, Franck-Miclo A, et al. Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia-reperfusion injuries In vivo. J Control Release 2011;156:146–53.

73. Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han Y-C, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature. 2014;516:423– 427.

74. Wang D, Mou H, Li S, Li Y,Hough S, Tran K, Li J, Yin H, Anderson DG, Sontheimer EJ et al.: Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther. 2015;26:432-442.

75. Zuckermann M, Hovestadt V, Knobbe-Thomsen CB, Zapatka M, Northcott PA, Schramm K, Belic J, Jones DT, Tschida B, Moriarity B et al.: Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat Commun. 2015;6:7391.

76. O'Rourke KP, Loizou E, Livshits G, Schatoff EM, Baslan T, Manchado E, Simon J, Romesser PB, Leach B, Han T et al.: Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat Biotechnol. 2017;35:577.

77. Chow RD, Guzman CD, Wang G, Schmidt F, Youngblood MW, Ye L, Errami Y, Dong

MB, Martinez MA, Zhang S et al.: AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci. 2017;20:1329-1341.

78. Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sa´nchez- Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D et al.: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015;21:1163.

79. Ideno N, Yamaguchi H, Okumura T, Huang J, Brun MJ, Ho ML, Suh J, Gupta S, Maitra A, Ghosh B: A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination. Lab Invest; 2019.

80. Maresch R, Mueller S, Veltkamp C, Ollinger R, Friedrich M, Heid I, Steiger K, Weber J, Engleitner T, Barenboim M et al.: Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice. Nat Commun. 2016;7:10770.

81. Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Ollinger R, Zwiebel M, Strong A et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554:62-68.

82. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, Sasaki N, Boymans S, Cuppen E, van der Ent CK, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13:653–658.

83. Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159:440–55.

84. Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol. 2014;32:941–6. DOI:10.1038/nbt.2951

85. Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O'Connor L, Milla L, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations invivo. Cell Rep. 2015;10:1422–32.

DOI:10.1016/j.celrep.2015.02.002

86. Malina A, Mills JR, Cencic R, Yan Y, Fraser J, Schippers LM, et al. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev. 2013;27:260214.

87. Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014;25:652–65.

88. Kraft K, Geuer S, Will AJ, Chan WL, Paliou C, Borschiwer M, et al. Deletions, inversions, duplications: engineering of structural variants using CRISPR/Cas in mice. Cell Rep. 2015;10:833–9.

89. Lagutina IV, Valentine V, Picchione F, Harwood F, Valentine MB, Villarejo-Balcells B, Carvajal JJ, Grosveld GC. Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR.Cas9 nuclease. PLoS Genet. 2015;11:e1004951.

90. Xiao A, Wang Z, Hu Y, Wu Y, Luo Z, Yang Z, Zu Y, Li W, Huang P, Tong X, et al. Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res. 2013;41. DOI:10.1093/nar/gkt464

91. Wang G, Chow RD, Ye L, Guzman CD, Dai X, Dong MB, Zhang F, Sharp PA, Platt RJ, Chen S. Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR–mediated direct In vivo screening. Sci. Adv. 2018; 4:eaao5508.

92. Lin Y, Cradick TJ, Brown MT, Deshmukh H, Ranjan P, Sarode N et al. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences, Nucleic Acids Research. 2014;42(11):7473-85.

93. Guernet SK, Mungamuri D, Cartier, R. Sachidanandam, A. Jayaprakash, S. Adriouch, et al., CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations, Molecular cell. 2016;63 (3):526-38.

94. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 2013;154:1370–1379.

95. Zetsche B, Volz SE, Zhang F. A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol. 2015;33:139–42.

96. Wright AV, Sternberg SH, Taylor DW, Staahl BT, Bardales JA, Kornfeld JE, et al. Rational design of a split-Cas9 enzyme complex. Proc Natl Acad Sci U S A. 2015;112:2984–9.

97. Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods. 2013;10:1116–21.

98. Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A. 2013;110:15644–9.

99. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186–91.

100. Baltimore BD, Berg P, Botchan M, Carroll D, Charo RA, Church G, et al. A prudent path forward for genomic engineering and germline gene modification. Science. 2015; 348:36–8.

101. Tsai SQ, Zheng Z, Nguyen NT, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33:187–97.

102. Kim D, Bae S, Park J, et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods. 2015;12:237– 43, 1 p following 243.

103. Wang X, Wang Y, Wu X, et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol 2015;33:175–8.

104. Roy I, Mitra S, Maitra A, et al. Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. Int J Pharm. 2003;250:25–33.

105. Lu QL, Liang HD, Partridge T, et al. Microbubble ultrasound improves the efficiency of gene transduction in skeletal muscle in vivo with reduced tissue damage. Gene Ther. 2003;10:396– 405.

106. Bekeredjian R, Chen S, Frenkel PA, et al. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation. 2003;108: 1022–6.

107. Liu XS, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S, Shu J, Dadon D, Young RA, Jaenisch R: Editing DNA Methylation in the Mammalian Genome. Cell 2016;167:233-247.

108. Lei Y, Zhang XT, Su JZ, Jeong M, Gundry MC, Huang YH, Zhou YB, Li W, Goodell MA: Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein. Nat Commun. 2017;8:16026

109. Liu SJ, Malatesta M, Lien BV, Saha P, Thombare SS, Hong SJ, Pedraza L, Koontz M, Seo K, Horlbeck MA: CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. Genome Biol 2020, 21:83.

110. Nihongaki Y, Yamamoto S, Kawano F, Suzuki H, Sato M. CRISPR-Cas9-based photoactivatable transcription system. Chem Biol. 2015;22:169–74.

111. Polstein LR, Gersbach CA. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol. 2015;11:198–200.

112. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008; 135:852–64.

113. Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2014;160: 1246–60.

114. MacLeod RS, Cawley KM, Gubrij I, Nookaew I, Onal M,O'Brien CA: Effective CRISPR interference of an endogenous gene via a single transgene in mice. Sci Rep. 2019;9:17312.

115. Isaev AB, Musharova OS, Severinov KV. Microbial arsenal of antiviral defenses. Part I, Biochemistry (Moscow). 2021;86:319-337.
DOI: 10.1134/S0006297921030081.

116. Horvath P, Barrangou R, Fremaux C, Boyaval P, Romero D. Use of a Cas Gene in Combination with CRISPR Repeats for Modulating Resistance in a Cell. US Patent Application No. PCT/US2006/033167 (initially f iled on 26.08.2005); 2007.

117. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144:646-674.

118. Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann. Surg. 2000;232:58–65.

119. Qin W, Dion SL, Kutny PM, Zhang Y, Cheng AW, Jillette NL, et al. Efficient CRISPR/cas9- mediated genome editing in mice by zygote electroporation of nuclease. Genetics. 2015;200:423–30. DOI:10.1534/genetics.115.176594

120. Hashimoto M, Takemoto T. Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas-based genome editing. Sci Rep. 2015;5:1–8. DOI:10.1038/ srep11315

121. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High- frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822–6. DOI:10.1038/nbt.2623

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/118453